Metformin is one of the most widely prescribed drugs for the treatment of diabetes, as their safety profile and effectiveness is very high, it can also be useful in combination with other drugs.
According to various scientific studies, metformin has a history of reducing the risk of cancer in patients with diabetes and reduces inflammation. Under this framework, Mexican scientists study the incidence of the drug in wound healing, and found that retards the proliferation of cells involved in the process.
Research leader Julio Enrique Castañeda Delgado mentions that in an in vitro model of skin cells (keratinocytes), they found that metformin reduced their proliferative capacity in the process healing.
Then the team of researchers confirmed the same results in animal models, so they decided to study if this phenomenon occurred also in humans. Therefore, they analyzed records of patients with diabetic foot ulcers who were treated with metformin.
“We found that at hospital admission, patients with diabetes taking metformin had a higher ulcer compared to those not taking it. Paradoxically, when analyzing the risk of amputation, although subjects taking the drug take more time to heal their wounds, they showed lower risk of losing a limb,” Castañeda Delgado said.
“Metformin is not a hypoglycemic as such, but acts with sensitivity to insulin. It has anti-inflammatory effects and this may explain the protective effect we found against amputation“, he added.
The research also included the important participation of Cervantes Alberto Rafael Villagrana, Doctor of biomedical sciences, professor researcher at the Academic Unit of Chemistry at the Autonomous University of Zacatecas and member of the National System of Researchers.
Source: Agencia ID